Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 23, 2026 12:30 ET | Source: Custom Market Insights

Global Preclinical Medical Device Testing Services Market Size/Share Worth USD 9.60 Billion by 2035 at a 9.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis)

Austin, TX, USA, July 23, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Preclinical Medical Device Testing Services Market Size, Trends and Insights By...
July 21, 2026 02:00 ET | Source: OMEICOS Therapeutics GmbH

OMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases (PMD) Following Positive End-of-Phase 2 Meeting with the FDA

OMEICOS has successfully completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA enabling a pivotal study in Primary Mitochondrial Disease (PMD).
July 15, 2026 08:30 ET | Source: BioAdaptives Inc.

BioAdaptives® Inc. Announces XcellaraHeart™, a Cardiovascular Wellness Formula Built on Xcellara’s Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells

LAS VEGAS, July 15, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT), developer of the Xcellara™ line of stem cell mobilization supplements, today announced the upcoming commercial...
June 26, 2026 09:32 ET | Source: BCC Research LLC

Cardiovascular Drugs Market to Reach New Heights by 2030, Driven by Rising Disease Prevalence and Innovation

BCC Research analyzes patent activity, clinical trials, AI adoption and competitive dynamics shaping the global cardiovascular drugs market through 2030.
June 24, 2026 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals Receives FDA Orphan Drug Designation for Ninerafaxstat for Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc. (Imbria), a clinical-stage company developing innovative therapeutics for cardiovascular diseases, today announced that the...
June 17, 2026 09:45 ET | Source: Octane

Octane Launches Mussallem Cardiovascular Accelerator to Advance Next Generation of Heart Health Innovation

Thanks to the support of the Linda and Mike Mussallem Foundation, Octane has launched the Octane Mussallem Cardiovascular Accelerator.
June 09, 2026 00:30 ET | Source: Custom Market Insights

[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Austin, TX, USA, June 09, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Generic Drug Market Size, Trends and Insights By Brand (Branded generic drugs,...
May 13, 2026 14:09 ET | Source: Vanotech Ltd

Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations

CHENGDU, China and ROCKAWAY, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced today that the US FDA granted...
May 06, 2026 08:30 ET | Source: Bioxodes

Bioxodes presents positive final Phase 2a intracerebral hemorrhage results at ESOC affirming breakthrough potential of BIOX-101

Final results confirm and build on interim BIRCH results in 23 ICH patients Primary safety endpoint met with no mortality observedEncouraging efficacy signals on all clinical and biomarker endpoints...
April 28, 2026 02:30 ET | Source: Bioxodes

Bioxodes to present final Phase 2a trial results confirming breakthrough potential of BIOX-101 for intracerebral hemorrhage in poster at ESOC 2026

Final results of BIRCH multicenter, randomized, open-label Phase 2a proof-of-concept BIRCH trial with 23 patients, conducted in BelgiumFinal results build on positive second interim results announced...